Therapeutic Development for Developmental, Psychiatric, and Substance Use Disorders – AN (12)
This review panel reviews applications dealing with basic and clinical aspects of drug discovery in treatment of developmental cognitive disorders, and psychiatric, mood, eating, sleep, and substance use disorders. Approach focuses are medicinal chemistry and pre-clinical therapeutic development, toxicology, and some clinical studies to establish proof-of-principle for new or repurposing existing drugs. The arrange of therapeutic formats include small molecule drugs and biologics such as molecular manipulation and engineering, gene and stem cell therapies, and proteins/neuropeptides that interact with and modulate neuroreceptors, transporters and transducers.
Review Dates
Topics
- Developmental mental and cognitive disorders such as autism spectrum disorder, Down syndrome, fragile X syndrome, and other congenital cognitive disorders/impairment
- Psychiatric disorders such as obsessive compulsory disorders, psychosis, schizophrenia, etc.
- Mood and anxiety disorders such as depression, anhedonia, bipolar disorder, post-traumatic stress disorder (PTSD), suicide, etc.
- Neurodegenerative diseases-accompanied neuropsychiatric symptoms including aggression, depression, anxiety, apathy, agitation, psychosis, etc.
- Sleep disorders
- Alcoholism and substance use disorders
- Eating disorders
